CD274 and neoplasm: For instance, combining PD-L1 inhibitors with agents targeting specific RCD pathways (i.e., ferroptosis inducers or necroptosis inhibitors) could enhance therapeutic efficacy by simultaneously disrupting multiple tumor survival mechanisms.